Andrew X. ZHU, MD, PhD
- Jiahui International Cancer Center
- Medical Oncology
- Jiahui International Hospital (Shanghai)
- Languages:普通话, English
Dr. Andrew X. Zhu, MD, PhD, is the Honorary Director of Jiahui International Cancer Center (JICC). Dr. Andrew X. Zhu is an internationally recognized leader in hepatocellular carcinoma(HCC) and cholangiocarcinoma, Dr. Zhu has served as a principle investigator in many pivotal clinical trials in HCC, cholangiocarcinoma and other gastrointestinal cancers.
Dr. Andrew X. Zhu is a founding board member of the International Liver Cancer Association(ILCA), Fellow of American College of Physicians (ACP), and a member of the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR) and former Professor of Medicine at Harvard Medical School.
Dr. Andrew X. Zhu established the multidisciplinary liver cancer clinic and conference at Massachusetts General Hospital in 2009. The hepatobiliary cancer MDT included experts from Surgical Oncology, Transplant Surgery, Interventional Radiology, Radiation Oncology, Hepatology and Pathology. In addition, Dr. Andrew X. Zhu led a series of pivotal clinical studies in advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma(BTC) during his tenure as director of Liver Cancer Research at the Mass General Cancer Center. As the lead global principal investigator, he led the pivotal studies which led to the regulatory approval of pembrolizumab and ramucirumab in advanced HCC. As a co-principal investigator, he is lead the phase III trial of first IDH-1 inhibitor Ivosidenib in cholangiocarcinoma with IDH-1 mutations, which has met the primary endpoint. Under the leadership of Dr. Andrew X. Zhu, he and his team established the hepatocellular cancer treatment center in New England, USA, which has become one of the most active clinical research centers for liver cancer in the United States.